Spots Global Cancer Trial Database for placebo for pembrolizumab
Every month we try and update this database with for placebo for pembrolizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | NCT03740165 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Pembrolizumab Placebo for pem... Carboplatin Paclitaxel Olaparib Placebo for ola... Bevacizumab Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | NCT03675737 | Stomach Neoplas... | Pembrolizumab Cisplatin 5-fluorouracil oxaliplatin capecitabine Placebo for Pem... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | NCT04634877 | Endometrial Neo... | Pembrolizumab Carboplatin Paclitaxel Placebo for pem... Docetaxel Cisplatin External Beam R... Cisplatin (as r... Brachytherapy | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension | NCT04859582 | Stomach Neoplas... | Pembrolizumab Cisplatin 5-fluorouracil Oxaliplatin Capecitabine Placebo for Pem... | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | NCT05116189 | Ovarian Cancer Carcinoma, Ovar... Fallopian Tube ... | Pembrolizumab Paclitaxel Bevacizumab Placebo for pem... Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | NCT03675737 | Stomach Neoplas... | Pembrolizumab Cisplatin 5-fluorouracil oxaliplatin capecitabine Placebo for Pem... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | NCT04221945 | Uterine Cervica... | Pembrolizumab Placebo for pem... Cisplatin External Beam R... Brachytherapy | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | NCT05116189 | Ovarian Cancer Carcinoma, Ovar... Fallopian Tube ... | Pembrolizumab Paclitaxel Bevacizumab Placebo for pem... Docetaxel | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
